Journal profile · Psychiatry
Pharmacopsychiatry
ISSN 0176-3679 · eISSN 1439-0795 · Georg Thieme Verlag · GERMANY · Bimonthly · Founded 1984
Pharmacopsychiatry: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.31; hybrid open access; APC about USD 3,620; review 6–12 weeks (community reports); community-reported acceptance: fairly easy; 66 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Pharmacopsychiatry is published by Georg Thieme Verlag and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Schizophrenia research and treatment, Treatment of Major Depression and Bipolar Disorder and Treatment, together about 32.6% of its articles. Its main subfields are Psychiatry and Mental health. (generated from OpenAlex topic counts and CAS ranking data)
Target ReadershipPharmacopsychiatry is intended for psychiatrists, neuroscientists, clinicians, and researchers working in the field of psychotropic drugs. It serves readers seeking key clinical insights as well as those interested in advances in psychopharmacology, biological psychiatry, neuroimaging, neurophysiology, and related neuroscientific disciplines.Journal Purpose and Mission The journal covers advances in the field of psychotropic drugs and provides psychiatrists, neuroscientists, and clinicians with key clinical insights while describing new avenues of research and treatment. It discusses the pharmacological and neurobiological bases of psychiatric disorders by presenting clinical and experimental research.Types of Articles PublishedPharmacopsychiatry publishes the following article types, Original Paper, Review, Letter to the Editor, Editorial, and Commentary.Publication FrequencyPharmacopsychiatry publishes 6 issues per annum.Subject and Content ScopeThe journal’s content encompasses advances in psychotropic drugs, clinical insights, and emerging research and treatment approaches. It covers the pharmacological and neurobiological bases of psychiatric disorders through clinical and experimental research. Its subject areas include basic, translational, and clinical psychopharmacology; biological psychiatry; neuroimaging and neurophysiology; basic and clinical neurosciences; biological psychology; and pharmacogenetics.
From the journal's Aims & Scope
Research area (LetPub): Psychiatry
Editorial board by country: 2 in mainland China (about 3%); most named Germany 32, United States 5, Japan 5, Switzerland 4, Canada 3 (58 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Schizophrenia research and treatmentMedicine13.1%
- Treatment of Major DepressionMedicine12.3%
- Bipolar Disorder and TreatmentMedicine7.3%
- Electroconvulsive Therapy StudiesMedicine6.6%
- Neurotransmitter Receptor Influence on BehaviorNeuroscience6%
- Tryptophan and brain disordersNeuroscience4.9%
- Stress Responses and CortisolNeuroscience4.4%
- Attention Deficit Hyperactivity DisorderMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
| Minor | Psychiatry | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Psychiatry | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Psychiatry | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.31LetPub ·
- Impact factor (publisher)
- 3.2Publisher website ·
- CiteScore 2026-06
- 7.6LetPub ·
- SJR 2026-06
- 0.87LetPub ·
- SNIP 2026-06
- 1.2LetPub ·
- h-index
- 73LetPub ·
- h-index
- 107OpenAlex ·
- i10-index
- 1,826OpenAlex ·
- 2-year mean citedness
- 1.53OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 17.24%LetPub ·
Volume
- Articles per year
- 23LetPub ·
Articles by year OpenAlex count · 5,666 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 41 | 7 | 29 |
| 2025 | 66 | 18 | 42 |
| 2024 | 94 | 22 | 237 |
| 2023 | 34 | 16 | 158 |
| 2022 | 91 | 21 | 406 |
| 2021 | 40 | 14 | 819 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | EUR 3,390 / USD 3,620 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted5
- commentaryPharmacopsychiatry publishes the following article types, Original Paper, Review, Letter to the Editor, Editorial, and Commentary.Publication FrequencyLength not stated
- editorialPharmacopsychiatry publishes the following article types, Original Paper, Review, Letter to the Editor, Editorial, and Commentary.Publication FrequencyLength not stated
- letter to the editorPharmacopsychiatry publishes the following article types, Original Paper, Review, Letter to the Editor, Editorial, and Commentary.Publication FrequencyLength not stated
- original paperPharmacopsychiatry publishes the following article types, Original Paper, Review, Letter to the Editor, Editorial, and Commentary.Publication FrequencyLength not stated
- reviewPharmacopsychiatry publishes the following article types, Original Paper, Review, Letter to the Editor, Editorial, and Commentary.Publication FrequencyLength not stated
Policy excerpts from the journal's websiteOpen access, Peer review
- Open access Publish Open Access
Open Access publishing is available via APC for this journal. Model summary
Authors of articles for all Thieme subscription journals – including, of course, Pharmacopsychiatry - have the option of paying an article processing charge (APC) so that their articles will be published on an Open Access basis. Learn more about Thieme’s Open Access program by visiting the link below. For the current pricing, please go to “APC” and select “Price List” ("Hybrid Open Access" price a…
Source ↗Publisher website ·- Peer review
Journal Policies, General Author Guidelines, Open Access Guidelines for Peer Reviewer links are provided. Model summary
Links Journal Policies General Author Guidelines Open Access Guidelines for Peer Reviewer
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Georg Thieme Verlag
- Country or region
- GERMANY
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1984
- ISSN
- 0176-3679
- Electronic ISSN
- 1439-0795
- Society / sponsor
- Leading Societies
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Pharmacopsychiatry
What CAS zone is Pharmacopsychiatry in?
In the 2025 upgraded edition of the CAS Journal Ranking, Pharmacopsychiatry is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy / Psychiatry. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Pharmacopsychiatry?
The latest impact factor listed by LetPub is 2.31; CiteScore 7.6, h-index 107.
How long does peer review take at Pharmacopsychiatry?
Authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Pharmacopsychiatry based?
Of the 58 board members whose country the journal's board page names, 2 (about 3%) are in mainland China; the countries named most often are Germany (32), United States (5) and Japan (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Pharmacopsychiatry?
According to LetPub and DOAJ records, Pharmacopsychiatry is indexed in SCIE and Scopus.
Is Pharmacopsychiatry open access, and what is the APC?
Pharmacopsychiatry is a hybrid journal. For open-access publication: APC about USD 3,620.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .